Viking’s stock plummets on obesity pill trial results
Viking Therapeutics’ dual-targeting oral weight loss drug has disappointed investors after it showed lower efficacy than offerings from pharma giants…
Latest News
-
-
RFK Jr’s mRNA funding halt signals “shift in US public health”
Robert F Kennedy, Jr (RFK Jr) has announced plans to cut government funding to messenger RNA (mRNA) vaccine development run…
-
US-China tensions offer new opportunity for APAC biotechs, report suggests
Investors are increasingly focused on biotech companies outside of China operating in the Asia-Pacific (APAC) market, according to a report…
-
Sandoz bolsters in-house biosimilar manufacturing with Evotec acquisition
In a bid to boost its presence in the lucrative biosimilar space, Sandoz has signed a non-binding agreement to buy…
-
GSK’s speciality medicines soar while generals drop, Q2 results reveal
UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its current portfolio.…
-
Apnimed sets sights on sleep apnoea pill approval following Phase III win
Following the success of its second Phase III trial on its investigative sleep apnoea medication, Apnimed has doubled down on…
-
Novo Nordisk defeated in Wegovy patent dispute by Viatris
Danish weight-loss giant Novo Nordisk has lost a US patent to generics manufacturer Viatris. A federal district court in Delaware…
-
Sarepta refuses to pull gene therapy despite FDA request
Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the US Food and…
-
GSK’s Blenrep faces setback as FDA cancer committee votes against approval
The US Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) has voted against the benefit/risk profile of GSK’s Blenrep (belantamab…
-
PEPFAR funding protection offers “hope” for people living with HIV
The White House’s decision to safeguard $400m in President's Emergency Plan for AIDS Relief (PEPFAR) funding to support the global…
